Search Results
11 protocol(s) meet the specified criteria
100314Open  
Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

110969Open  
Phase I Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

112811Open  
Phase IB/II Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Binimetinib with or without Talazoparib in Patients with Locally Advanced or Metastatic RAS-Mutant Solid Tumors

114610Open  
Phase II Trial of Osimertinib with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

81405Not Open *
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

90521Open  
Phase II, Multicenter, Four-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (WT), Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease

95965Open  
Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) versus Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

97414Not Open *
Randomized, Open-Label, Phase III Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors